Compare Repligen Corporation Common Stock (RGEN) vs Somnigroup International Inc. Common Stock (SGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Somnigroup International Inc. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Somnigroup International Inc. Common Stock trades at $62.83 (market cap $14.28B). The key difference: Somnigroup International Inc. Common Stock is the larger of the two by market cap, and Somnigroup International Inc. Common Stock pays a 1.1% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Somnigroup International Inc. Common Stock for 0 Days on average.
| RGEN | SGI | |
|---|---|---|
Market Cap | $11.31B | $14.28B |
Volume | 1,216,919 | 2,254,312 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $97.99 |
52-Week Low | $102.87 | $61.49 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $11.20B | $20.58B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Somnigroup International (SGI) trades at $62.87, up 0.75% with neutral technical signals. The company shows strong profitability with 44.24% gross margins and has beaten earnings estimates for three consecutive quarters. Recent acquisition of Leggett & Platt enhances vertical integration with $75M synergy target. Analyst consensus is strongly bullish with 91% buy ratings and $94.50 price target, representing 50% upside potential from current levels.
SGI presents compelling growth prospects through strategic acquisitions and operational efficiencies, though faces margin pressures in weak bedding markets. The stock trades at reasonable valuations (P/E 24.85) with improving cash flow trends expected in 2026. Key risks include integration execution and market competition, but strong institutional interest and insider buying support the bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Somnigroup International Inc. Common Stock
Somnigroup International Inc. (formerly Tempur Sealy International) is a bedding and sleep-products company that designs, manufactures, distributes, and retails mattresses and related products. It operates through Tempur Sealy North America, Tempur Sealy International, and Mattress Firm, with brands including Tempur-Pedic, Sealy, Stearns & Foster, and Mattress Firm.
Read more on SGI →
